-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38

Benzinga·10/27/2026 16:52:04
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.